Avoro Capital Advisors’s Tourmaline Bio TRML Stock Holding History

Avoro Capital Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,555,555	Closed	-$122M	–	43
2025 Q3	$122M	Hold	2,555,555	–	–	1.58%	18
2025 Q2	$40.9M	Buy	2,555,555 +130,555	+5%	+$2.12M	0.72%	24
2025 Q1	$36.9M	Buy	2,425,000 +202,778	+9%	+$3.25M	0.58%	26
2024 Q4	$45.1M	Hold	2,222,222	–	–	0.64%	25
2024 Q3	$57.1M	Hold	2,222,222	–	–	0.83%	24
2024 Q2	$28.6M	Hold	2,222,222	–	–	0.38%	34
2024 Q1	$50.9M	Buy	2,222,222 +1,353,815	+156%	+$47.7M	0.59%	31
2023 Q4	$22.7M	Buy	868,407 +818,407	+1,637%	+$16.4M	0.31%	36
2023 Q3	$1.41M	Hold	50,000	–	–	0.02%	44
2023 Q2	$1.52M	Buy	+50,000	New	+$1.28M	0.02%	42

Avoro Capital Advisors's TRML Position: Q4 2025 in Review

Avoro Capital Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 2,555,555 shares — an estimated $122M sold.

Avoro Capital Advisors first reported a position in TRML in Q2 2023 and held it in 10 quarters. The position peaked at $122M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Avoro Capital Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Avoro Capital Advisors sold 2,555,555 Tourmaline Bio shares in Q4 2025, an estimated $122M.
Avoro Capital Advisors first reported a position in Tourmaline Bio in Q2 2023 and held it in 10 quarters.
Avoro Capital Advisors's Tourmaline Bio position peaked at $122M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Avoro Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.